In this age of rapid innovation, it's critical to keep up with advances and trends, and to exchange ideas with international colleagues. This event is designed to provide insights that optimize tasks at the bench with an emphasis on 'real-world' experience
Needham, MA (PRWEB) June 30, 2010
Practical solutions and protocols will once again be exchanged at Cambridge Healthtech Institute's second annual "The Bioprocessing Summit " taking place August 23-26, 2010, in Boston. The four meetings comprising the event (Optimizing Cell Culture Technology, Affinity Tag Protein Purification, Optimizing Mammalian Cell Lines, and Baculovirus Technology) will address bioprocess challenges ranging from cell line and clone selection to scale-up and affinity tag purification. The Summit will bring together leaders in the field to present the most helpful information for those working with insect and mammalian cells, expressing proteins, and creating cell-based products.
"In this age of rapid innovation, it's critical to keep up with advances and trends, and to exchange ideas with international colleagues. This event is designed to provide insights that optimize tasks at the bench with an emphasis on 'real-world' experience," says Mary Ruberry, Conference Director of Cambridge Healthtech Institute.
John Mott, Director of Cell Line Development & Global Biologics at Pfizer, will kick off the sixth annual "Optimizing Cell Culture Technology" meeting with a focus on CHO (Chinese Hamster Ovary). The agenda is chock-full of expert strategies and insights such as optimizing the culture environment through cell corpse clearance, using DOE ("Design of Experiments") to improve cell culture conditions, and improving bioreactor performance with dynamic membrane aeration.
The second annual "Affinity Tag Protein Purification" meeting explores the world of affinity tags - the benefits and drawbacks of each - including alternative affinity methods. Breakthrough techniques will be discussed including photocleavable tags, autoprocessing tags, epitope tags, and overcoming cleavage challenges.
Transfection, Electroporation and Clone Screening highlight the second annual "Optimizing Mammalian Cell Lines" meeting including site specificity and phototransfection. Joseph Shiloach, Chief of the Biotechnology Unit at NIDDK/NIH, will initiate the discussion of cell line development by addressing the use of microarrays to modify cellular properties.
The baculovirus system has achieved widespread recognition and use, as illustrated in the fourth annual "Baculovirus Technology" meeting with sessions focused on Screening, Vector Design, Protein Expression, and Vaccine Development. Seminal talks on biological properties will be presented by Paul Friesen from the University of Wisconsin, James Groarke from Novartis, and Gary Blissard of Cornell.
Along with the main conference sessions, three workshops will be presented to allow a more in-depth focus on important topics, such as Optimizing Cell Culture Media, Affinity Tag Purification Systems, and using E.coli for protein expression and purification. This year's Exhibit Hall will feature an expanding number of exhibit booths and extensive poster presentations.
For more information on The Bioprocessing Summit, please visit the event website at http://www.bioprocessingsummit.com.
About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (CHI) (http://www.chicorporate.com), founded in 1992, is the industry leader in providing superior-quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.
Contact: Kaushik Chaudhuri
Cambridge Healthtech Institute